---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-287163"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:26:03.015786+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics to acquire four CAR T assets in all-stock deal; CEO change, warrants issued

## Summary
- Acquires ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies for 8,268,495 shares of TPST common stock.
- Post-closing, existing TPST holders own ~35%; Erigen equityholders (Matt Angel and Lotus Capital) own ~38% and ~27% on fully diluted basis.
- Matt Angel appointed President & CEO; Stephen Brady becomes Chairman; Geoff Nichol resigns from board, effective at closing.
- Each TPST share to receive one warrant exercisable at $18.48 per share, valid for 5 years from issue date.
- Closing requires stockholder approval, Angel's appointment, and a minimum $5M pre-closing financing; expected early 2026.

## SEC filing metadata
- accession: 0001193125-25-287163
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312525287163/0001193125-25-287163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312525287163/d97617d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-287163
- JSON: https://secwatch.observer/filing/0001193125-25-287163.json
- Plain text: https://secwatch.observer/filing/0001193125-25-287163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.